Hemolysis after administration of high-dose immunoglobulin in a patient with myocarditis

Basit Öğe Kaydı
dc.contributor.authorKaraaslan S.
dc.contributor.authorOran B.
dc.contributor.authorÇalişkan U.
dc.contributor.authorBaysal T.
dc.contributor.authorBaşpinar O.
dc.contributor.authorTaş A.
dc.date.accessioned2020-03-26T16:46:36Z
dc.date.available2020-03-26T16:46:36Z
dc.date.issued2003
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe use of high-dose intravenous immunoglobulin (IVIG) has greatly increased in the last years. With broader use of immunoglobulin, the numbers of reported side effects are also growing. IVIG have also been used in the treatment of myocarditis and dilated cardiomyopathy. Here we reported a child with presumed acute myocarditis who has developed severe hemolytic anemia following high-dose IVIG administration. As our knowledge, this is the first case report with myocarditis or dilated cardiomyopathy who developed hemolytic anemia following high-dose IVIG administration.en_US
dc.identifier.endpage240en_US
dc.identifier.issn1300-7777en_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage237en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/18692
dc.identifier.volume20en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Haematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAnemiaen_US
dc.subjectCardiomyopathyen_US
dc.subjectHemolyticen_US
dc.subjectImmunoglobulin therapyen_US
dc.titleHemolysis after administration of high-dose immunoglobulin in a patient with myocarditisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
document (3).pdf
Boyut:
202.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu